Parvovirus in Dogs
![]() |
---|
KIND-030 – Parvovirus in dogs
|
KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is being pursued for two indications: Prophylactic therapy to prevent clinical signs of CPV infection, and treatment of established CPV infection.
Positive results from pivotal efficacy study for the prophylactic indication. All placebo-control dogs developed parvovirus infection, while none of the KIND-030 dogs developed the disease. Mortality benefit in treated group also observed.
References:
1. Altman KD, Kelman M, Ward MP. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure? Vet Microbiol. 2017; 210:8-16.
2. Banfield Pet Hospital. State of Pet Health Report(tm) 2014. Available at: https://www.banfield.com/Banfield/media/PDF/Downloads/soph/Banfield-State-of-Pet-Health-Report_2014.pdf [Access date: March 17, 2020].
3. Wilson S, Illambas J, Siedek E, et al. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c. Vaccine. 2014;32(42):5420-5424.
4. Greene CE, Decaro N. Canine viral enteritis. In: Green CE, ed. Infectious Diseases of the Dog and Cat, 4th ed. St. Louis, MO: Elsevier Saunders; 2012:67-80.
5. Venn EC, Preisner K, Boscan PL, et al. Evaluation of an outpatient protocol in the treatment of canine parvoviral enteritis. J Vet Emerg Crit Care (San Antonio). 2017;27(1):52-65.
6. Kelman M, Ward MP, Barrs VR, Norris JM. The geographic distribution and financial impact of canine parvovirus in Australia. Transbound Emerg Dis. 2019;66(1):299-311.
7. Nandi S, Kumar M. Canine parvovirus: current perspective. Indian J Virol. 2010;21(1):31-44.
US-CORP-2000022 MAR-20